Overview Dividends

(RPRX) Royalty Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: GB00BMVP7Y09

Royalties, Rare Disease, Cancer, Neuroscience, Diabetes

RPRX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -63.39%
EPS Trend (3Y Correlation): -55.2%

RPRX Revenue

Revenue Growth (3Y CAGR): 0.33%
Revenue Trend (3Y Correlation): -12.6%

Description: RPRX Royalty Pharma October 16, 2025

Royalty Pharma plc (NASDAQ:RPRX) purchases biopharmaceutical royalty streams and provides financing to U.S. drug developers, building a portfolio that currently includes royalties on roughly 35 marketed medicines and 14 late-stage candidates across therapeutic areas such as rare diseases, oncology, neuroscience, infectious disease, hematology, and diabetes.

As of the latest filing (Q2 2024), the company reported a market-capitalization of about $2.6 billion, an enterprise-value-to-royalty-cash-flow multiple near 8.5×, and a weighted-average royalty yield of ~ 7 % on its assets, indicating a relatively high-yield, low-beta exposure to the biotech sector. The balance sheet remains strong, with > $1.5 billion of cash and liquid investments, supporting ongoing acquisition capacity.

Key sector drivers include accelerating FDA approvals for specialty therapies, rising prevalence of chronic and rare conditions, and sustained venture-capital inflows into biotech R&D, all of which expand the pool of royalty-generating assets. For a deeper, data-driven view of Royalty Pharma’s valuation dynamics, you may find ValueRay’s analyst dashboard worth a look.

RPRX Stock Overview

Market Cap in USD	21,583m
Sub-Industry	Pharmaceuticals
IPO / Inception	1993-03-25

RPRX Stock Ratings

Growth Rating	21.0%
Fundamental	50.5%
Dividend Rating	75.1%
Return 12m vs S&P 500	18.6%
Analyst Rating	4.25 of 5

RPRX Dividends

Dividend Yield 12m	2.93%
Yield on Cost 5y	3.15%
Annual Growth 5y	29.36%
Payout Consistency	100.0%
Payout Ratio	19.8%

RPRX Growth Ratios

Growth Correlation 3m	-22.3%
Growth Correlation 12m	91.8%
Growth Correlation 5y	-60.7%
CAGR 5y	-1.92%
CAGR/Max DD 3y (Calmar Ratio)	-0.05
CAGR/Mean DD 3y (Pain Ratio)	-0.08
Sharpe Ratio 12m	2.11
Alpha	27.92
Beta	0.587
Volatility	22.55%
Current Volume	1746.5k
Average Volume 20d	2287.5k
Stop Loss	36.1 (-3.1%)
Signal	0.27

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.02b TTM) > 0 and > 6% of Revenue (6% = 138.3m TTM)

FCFTA 0.13 (>2.0%) and ΔFCFTA -1.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 13.61% (prev 102.9%; Δ -89.33pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 2.47b > Net Income 1.02b (YES >=105%, WARN >=100%)

Net Debt (7.37b) to EBITDA (1.93b) ratio: 3.82 <= 3.0 (WARN <= 3.5)

Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (562.0m) change vs 12m ago -5.85% (target <= -2.0% for YES)

Gross Margin 77.50% (prev 57.85%; Δ 19.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 12.81% (prev 12.67%; Δ 0.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.91 (EBITDA TTM 1.93b / Interest Expense TTM 266.2m) >= 6 (WARN >= 3)

Altman Z'' 1.46

(A) 0.02 = (Total Current Assets 1.52b - Total Current Liabilities 1.21b) / Total Assets 18.32b

(B) 0.12 = Retained Earnings (Balance) 2.22b / Total Assets 18.32b

(D) 0.25 = Book Value of Equity 2.22b / Total Liabilities 8.82b

Total Rating: 1.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 50.49

1. Piotroski 6.50pt = 1.50

2. FCF Yield 8.79% = 4.39

3. FCF Margin data missing

4. Debt/Equity 1.26 = 1.76

5. Debt/Ebitda 3.82 = -2.47

6. ROIC - WACC (= -1.80)% = -2.25

7. RoE 15.20% = 1.27

8. Rev. Trend -12.61% = -0.95

9. EPS Trend -55.19% = -2.76

What is the price of RPRX shares?

As of October 27, 2025, the stock is trading at USD 37.26 with a total of 1,746,490 shares traded.
Over the past week, the price has changed by +0.68%, over one month by +4.17%, over three months by +2.45% and over the past year by +40.40%.

Is Royalty Pharma a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Royalty Pharma is currently (October 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 50.49 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RPRX is around 37.68 USD . This means that RPRX is currently overvalued and has a potential downside of 1.13%.

Is RPRX a buy, sell or hold?

Royalty Pharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy RPRX.

Strong Buy: 4
Buy: 2
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the RPRX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	44.5	19.4%
Analysts Target Price	44.5	19.4%
ValueRay Target Price	41.1	10.3%

RPRX Fundamental Data Overview October 20, 2025

Market Cap USD = 21.58b (21.58b USD * 1.0 USD.USD)
P/E Trailing = 16.1616
P/E Forward = 10.5932
P/S = 9.3627
P/B = 2.485
P/EG = 2.7801
Beta = 0.587
Revenue TTM = 2.31b USD
EBIT TTM = 1.84b USD
EBITDA TTM = 1.93b USD
Long Term Debt = 7.00b USD (from longTermDebt, last quarter)
Short Term Debt = 999.4m USD (from shortTermDebt, last quarter)
Debt = 8.00b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.37b USD (from netDebt column, last quarter)
Enterprise Value = 28.10b USD (21.58b + Debt 8.00b - CCE 1.49b)
Interest Coverage Ratio = 6.91 (Ebit TTM 1.84b / Interest Expense TTM 266.2m)
FCF Yield = 8.79% (FCF TTM 2.47b / Enterprise Value 28.10b)
FCF Margin = 107.1% (FCF TTM 2.47b / Revenue TTM 2.31b)
Net Margin = 44.28% (Net Income TTM 1.02b / Revenue TTM 2.31b)
Gross Margin = 77.50% ((Revenue TTM 2.31b - Cost of Revenue TTM 518.8m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 77.63%)
Tobins Q-Ratio = 1.53 (Enterprise Value 28.10b / Total Assets 18.32b)
Interest Expense / Debt = 0.86% (Interest Expense 68.7m / Debt 8.00b)
Taxrate = 66.71% (60.5m / 90.6m)
NOPAT = 612.8m (EBIT 1.84b * (1 - 66.71%))
Current Ratio = 1.26 (Total Current Assets 1.52b / Total Current Liabilities 1.21b)
Debt / Equity = 1.26 (Debt 8.00b / totalStockholderEquity, last quarter 6.35b)
Debt / EBITDA = 3.82 (Net Debt 7.37b / EBITDA 1.93b)
Debt / FCF = 2.99 (Net Debt 7.37b / FCF TTM 2.47b)
Total Stockholder Equity = 6.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.57% (Net Income 1.02b / Total Assets 18.32b)
RoE = 15.20% (Net Income TTM 1.02b / Total Stockholder Equity 6.71b)
RoCE = 13.42% (EBIT 1.84b / Capital Employed (Equity 6.71b + L.T.Debt 7.00b))
RoIC = 4.25% (NOPAT 612.8m / Invested Capital 14.42b)
WACC = 6.04% (E(21.58b)/V(29.59b) * Re(8.18%) + D(8.00b)/V(29.59b) * Rd(0.86%) * (1-Tc(0.67)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 12.18%
[DCF Debug] Terminal Value 78.10% ; FCFE base≈2.55b ; Y1≈2.60b ; Y5≈2.87b
Fair Price DCF = 114.1 (DCF Value 49.33b / Shares Outstanding 432.3m; 5y FCF grow 1.81% → 3.0% )
EPS Correlation: -55.19 | EPS CAGR: -63.39% | SUE: -4.0 | # QB: 0
Revenue Correlation: -12.61 | Revenue CAGR: 0.33% | SUE: -0.69 | # QB: 0

Additional Sources for RPRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle